BERYL DRUGS LIMITED
Gr. Floor, 133, Kanchan Bagh, Indore (M.P.) – 452 001.
Tel./ Fax 0731-3228696
E-mail : beryldrugs25@yahoo.com

ANNEXURE I

Submission of Unaudited/ Audited Financial Result by Companies Other than Banks

Part I

Statement of standalone / Consolidated / Audited Result for the Quarter/ year ended 31/03/2017

(Rs in 000)

	Particulars (Refer Notes Below)	3 months ended (31-03-2017)	Preceding 3 months ended (31-12-2016)	Corresponding 3 months ended in the previous year (31-03-2016)	Year to date figures for current period ended (31-03-2017)	Year to date figures for previous period ended (31-03-2016)	Previous year ended (31-03-2016)
		Audited	Unaudited	Unaudited	Audited	Audited	Audited
1	**Revenue From Operations**						
	Net sales or Revenue from Operations	23783.000	25758.000	16099.000	109935.000	131102.000	131102.000
	Other operating revenues	1341.000	353.000	817.000	2607.000	3711.000	3711.000
	Total Revenue from operations (net)	25124.000	26111.000	16916.000	112542.000	134813.000	134813.000
2	**Expenses**						
(a)	Cost of materials consumed	-2583.000	23204.000	11328.000	69020.000	88047.000	88047.000
(b)	Purchases of stock-in-trade	0.000	0.000	0.000	0.000	0.000	0.000
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	1467.000	-3997.000	-1948.000	-4459.000	-1947.000	-1947.000
(d)	Employee benefit expense	1819.000	2894.000	2564.000	9830.000	12092.000	12092.000
(e)	Depreciation and amortisation expense	770.000	1000.000	1051.000	3770.000	4101.000	4101.000
(f)	**Other Expenses**						
1	other expenses	23177.000	3354.000	4683.000	30529.000	27759.000	27759.000
	other expenses	0.000	0.000	0.000	0.000	0.000	0.000
	Total other expenses	23177.000	3354.000	4683.000	108690.000	27759.000	27759.000
	Total expenses	24650.000	26455.000	17678.000	108690.000	130050.000	130050.000
3	Profit (loss) from operations before other income, finance costs and exceptional items	474.000	-344.000	-762.000	3852.000	4762.000	4762.000
4	Other income	0.000	0.000	0.000	0.000	0.000	0.000
5	Profit (loss) from ordinary activates before finance costs and exceptional items	474.000	-344.000	-762.000	3852.000	4762.000	4762.000
6	Finance costs	469.000	547.000	471.000	2079.000	2054.000	2054.000
7	Profit (loss) from ordinary activities after finance costs but before exceptional items	5.000	-891.000	-1233.000	1773.000	2707.000	2707.000
8	Exceptional items	0.000	0.000	0.000	0.000	-251.000	-251.000
9	Profit (loss) from ordinary activities before tax	5.000	-891.000	-1233.000	1773.000	2456.000	2456.000
10	Tax Expense	207.000	0.000	10.000	607.000	790.000	790.000
11	Net profit (loss) from ordinary activities after tax	-202.000	-891.000	-1223.000	1166.000	1666.000	1666.000
12	Extraordinary items	0.000	0.000	0.000	0.000	0.000	0.000
13	Net profit (loss) for the period	-202.000	-891.000	-1223.000	1166.000	1666.000	1666.000
14	Share of profit (loss) of associates	0.000	0.000	0.000	0.000	0.000	0.000
15	Profit (loss) of minority interest	0.000	0.000	0.000	0.000	0.000	0.000
16	**Net Profit (loss) after taxes minority interest and share of profit (loss) of associates**	-202.000	-891.000	-1223.000	1166.000	1666.000	1666.000
17	**Details of equity share capital**						
	Paid-up equity share capital	50717.000	50717.000	50717.000	50717.000	50717.000	50717.000
	Face value of equity share capital	10.000	10.000	10.000	10.000	10.000	10.000
18	**Reserves excluding revaluation reserve**	17008.000	17442.000	15684.000	17008.000	15684.000	15684.000
19	**Earnings per share**						
i	**Earnings per share before extraordinary items**						
	Basic earnings per share before extraordinary items	0.000	0.000	0.000	0.230	0.328	0.328
	Diluted earnings per share before extraordinary items	0.000	0.000	0.000	0.230	0.328	0.328
ii	**Earnings per share after extraordinary items**						
	Basic earnings per share after extraordinary items	0.000	0.000	0.000	0.230	0.328	0.328
	Diluted earnings per share after extraordinary items	0.000	0.000	0.000	0.230	0.328	0.328

Notes :

1. The Standalone results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meeting held on 30th May 2017.
2. In accordance with the requirements of Clause 41 of the Listing Agreement with the Stock Exchange, the Statutory Auditors have performed a limited review of the Company's financial results for the quarter ended March 31, 2017 there are no qualifications.
3. The Income from Operations is from one segment namely "Pharmaceutical Indusrty".
4. Previous period exp. have been regrouped / rearranged, wherever necessary.
5. taxes and depreciation are calculated on proportionate basis on annual estimated basis.
6. There were no Investors complaints pending at the beginning of the quarter and one complaint were received during the quarter ended March 31, 2017.

Place : Indore
Date : 30.5.2017

For and behalf of the Board

BERYL DRUGS
Director

Sanjay Sethi
Managing Director